(Q53098576)

11 May 2018

title

LC-MS/MS method for the characterization of the forced degradation products of Entecavir. (English)

1 reference

11 May 2018

author name string

Thippani Ramesh

series ordinal

1

1 reference

11 May 2018

Pothuraju Nageswara Rao

series ordinal

2

1 reference

11 May 2018

Ramisetti Nageswara Rao

series ordinal

3

1 reference

11 May 2018

publication date

6 January 2014

1 reference

11 May 2018

Journal of Separation Science

published in

1 reference

11 May 2018

volume

37

1 reference

11 May 2018

issue

4

1 reference

11 May 2018

page(s)

368-375

1 reference

11 May 2018

The anti-HIV antiviral activity of entecavir: the loss of a trusted friend?

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Entecavir for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

A review of entecavir in the treatment of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Development and validation of a stability-indicating capillary zone electrophoretic method for the assessment of entecavir and its correlation with liquid chromatographic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

LC-MS/MS studies of ritonavir and its forced degradation products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Optimization of mobile phase for the determination of Esomeprazole and related compounds and investigation of stress degradation by LC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

Highly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography–ultra-high-performance liquid chromatography–tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJSSC.201300959

21 January 2018

Identifiers

DOI

10.1002/JSSC.201300959

1 reference

11 May 2018

1 reference

11 May 2018